41. Amerikan Klinik Kanser Cemiyeti (ASCO)-2005 toplantisindan izlenimler: Meme kanserinin adjuvan tedavisinde trastuzumab

Kadri Altundaǧ; Banu Arun

41. Amerikan Klinik Kanser Cemiyeti (ASCO)-2005 toplantisindan izlenimler: Meme kanserinin adjuvan tedavisinde trastuzumab

Translated title of the contribution: Reports from forty-first American Society of Clinical Oncology (ASCO)-2005 meeting: Trastuzumab use in the adjuvant treatment of breast cancer

Kadri Altundaǧ, Banu Arun

Breast Medical Oncology

Research output: Contribution to journal › Review article › peer-review

1 Scopus citations

Abstract

Trastuzumab (Herceptin), a humanized monoclonal antibody specific for HER-2, has been used successfully in the management of metastatic HER-2-overexpressing breast cancers. The clear efficacy of trastuzumab against HER-2-overexpressing metastatic breast cancer has led to a rationale in testing its adjuvant role in the management of early breast cancer. We summarize three important studies about the adjuvant use of trastuzumab in breast cancer patients presented in 41. ASCO annual meeting 2005.

Translated title of the contribution	Reports from forty-first American Society of Clinical Oncology (ASCO)-2005 meeting: Trastuzumab use in the adjuvant treatment of breast cancer
Original language	Turkish
Pages (from-to)	104-109
Number of pages	6
Journal	THOD - Turk Hematoloji-Onkoloji Dergisi
Volume	15
Issue number	2
State	Published - 2005

Keywords

Adjuvant
Breast cancer
Trastuzumab

ASJC Scopus subject areas

Hematology
Oncology

Cite this

@article{95e1a9e523254594a2038c0494b6ec6e,

title = "41. Amerikan Klinik Kanser Cemiyeti (ASCO)-2005 toplantisindan izlenimler: Meme kanserinin adjuvan tedavisinde trastuzumab",

abstract = "Trastuzumab (Herceptin), a humanized monoclonal antibody specific for HER-2, has been used successfully in the management of metastatic HER-2-overexpressing breast cancers. The clear efficacy of trastuzumab against HER-2-overexpressing metastatic breast cancer has led to a rationale in testing its adjuvant role in the management of early breast cancer. We summarize three important studies about the adjuvant use of trastuzumab in breast cancer patients presented in 41. ASCO annual meeting 2005.",

keywords = "Adjuvant, Breast cancer, Trastuzumab",

author = "Kadri Altundaǧ and Banu Arun",

year = "2005",

language = "Turkish",

volume = "15",

pages = "104--109",

journal = "THOD - Turk Hematoloji-Onkoloji Dergisi",

issn = "1301-8825",

publisher = "UHOD - Uluslararasi Hematoloji Onkoloji Dergisi",

number = "2",

}

TY - JOUR

T1 - 41. Amerikan Klinik Kanser Cemiyeti (ASCO)-2005 toplantisindan izlenimler

T2 - Meme kanserinin adjuvan tedavisinde trastuzumab

AU - Altundaǧ, Kadri

AU - Arun, Banu

PY - 2005

Y1 - 2005

N2 - Trastuzumab (Herceptin), a humanized monoclonal antibody specific for HER-2, has been used successfully in the management of metastatic HER-2-overexpressing breast cancers. The clear efficacy of trastuzumab against HER-2-overexpressing metastatic breast cancer has led to a rationale in testing its adjuvant role in the management of early breast cancer. We summarize three important studies about the adjuvant use of trastuzumab in breast cancer patients presented in 41. ASCO annual meeting 2005.

AB - Trastuzumab (Herceptin), a humanized monoclonal antibody specific for HER-2, has been used successfully in the management of metastatic HER-2-overexpressing breast cancers. The clear efficacy of trastuzumab against HER-2-overexpressing metastatic breast cancer has led to a rationale in testing its adjuvant role in the management of early breast cancer. We summarize three important studies about the adjuvant use of trastuzumab in breast cancer patients presented in 41. ASCO annual meeting 2005.

KW - Adjuvant

KW - Breast cancer

KW - Trastuzumab

UR - http://www.scopus.com/inward/record.url?scp=21344434811&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=21344434811&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:21344434811

SN - 1301-8825

VL - 15

SP - 104

EP - 109

JO - THOD - Turk Hematoloji-Onkoloji Dergisi

JF - THOD - Turk Hematoloji-Onkoloji Dergisi

IS - 2

ER -

41. Amerikan Klinik Kanser Cemiyeti (ASCO)-2005 toplantisindan izlenimler: Meme kanserinin adjuvan tedavisinde trastuzumab

Abstract

Keywords

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this